
    
      A baseline assessment was performed prior to the first dose of adalimumab. Participants
      received 40 mg of adalimumab every other week for one year. Study visits were conducted at
      12, 28, 36 and 52 weeks. All participants were to have one follow-up approximately 70 days
      after the last dose of adalimumab.
    
  